Pfizer Cancer Pact With Merck Shows Waning Astra Pursuit

Pfizer Inc. will pay $850 million for rights to a cancer drug being developed by Merck KGaA, giving the U.S. company an experimental treatment of the type that it sought when it made a hostile bid for AstraZeneca Plc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.